

אוקטובר 2024

רופא/ה נכבד/ה
רוקח/ת נכבד/ה,

חברת מדיסון פארמה בע"מ שמחה להודיעכם על אישור משרד הבריאות לתוספת ההתוויה עבור התכשיר:

Lonsurf 15 mg/6.14 mg
Lonsurf 20 mg/8.19 mg**לונסורף 15 מ"ג/6.14 מ"ג**
לונסורף 20 מ"ג/8.19 מ"ג**טבליות מצופות**

מרכיבים פעילים : tipiracil (as hydrochloride), trifluridine

התוויות מאושרות (ההתוויה החדשה מסומנת בצהוב):

Colorectal cancer

Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.

LONSURF in combination with bevacizumab, is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

Gastric cancer

Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

להלן העדכונים בעלון לרופא המהווים החמרות (מסומנים בצהוב):

4.2 Posology and method of administrationPosology

The recommended starting dose of Lonsurf in adults, **as monotherapy or in combination with bevacizumab**, is 35 mg/m²/dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 28-day cycle until disease progression or unacceptable toxicity (see section 4.4).

When Lonsurf is used in combination with bevacizumab for the treatment of metastatic CRC, the dose of bevacizumab is 5 mg/kg of body weight given once every 2 weeks. Please refer to the full product information for bevacizumab.

[...]

4.4 Special warnings and precautions for useBone marrow suppression

Medison Pharma Ltd.

10 Hashiloach St., P.O.B 7090, Petach-Tikva 4917002 Israel

Tel. +972. 3. 925. 0250, Fax. +972. 3. 922. 5740

medisonpharma.com

[...] In RECOURSE, TAGS and SUNLIGHT studies, 9.4%, 17.3% and 19.5% of patients in the Lonsurf group respectively received G-CSF mainly for therapeutic use. In the SUNLIGHT study, 29.3% of patients in the Lonsurf with bevacizumab group received G-CSF including 16.3% for therapeutic use.

[...]

4.6 Fertility, pregnancy and lactation

[...]

Fertility

[...] Patients who wish to conceive a child should be advised to seek reproductive counselling and cryo-conservation of either the ovum or sperm prior to starting Lonsurf treatment.

[...]

4.8 Undesirable effects

Summary of safety profile

[...]

Lonsurf in combination with bevacizumab

The safety profile of Lonsurf in combination with bevacizumab is based on the data from 246 patients with metastatic colorectal cancer in the controlled phase III clinical study (SUNLIGHT).

The most common adverse reactions ($\geq 30\%$) are neutropenia (69% [48% \geq Grade 3]), fatigue (35% [3% \geq Grade 3]), and nausea (33% [1% \geq Grade 3]).

The most common adverse reactions ($\geq 2\%$) that resulted in treatment discontinuation, dose reduction, dose delay, or dose interruption of Lonsurf when used in combination with bevacizumab were neutropenia, fatigue, thrombocytopenia, nausea and anaemia.

When Lonsurf is used in combination with bevacizumab, the frequency of the following adverse reactions was increased compared to Lonsurf as monotherapy: neutropenia (69% vs 53%), severe neutropenia (48% vs 34%), thrombocytopenia (24% vs 16%), stomatitis (11% vs 6%).

[...]

Adverse reactions known to occur with Lonsurf given alone or with bevacizumab may occur during treatment with these medicinal products in combination, even if these reactions were not reported in clinical trials with combination therapy.

[...]

Table 5 - Adverse reactions reported in clinical studies in patients treated with Lonsurf

System Organ Class (MedDRA) ^a	Adverse reactions	Frequency	
		Monotherapy	Combination with bevacizumab
Infections and infestations		[...]	
	infection	Uncommon	Common
	Urinary tract infection	Uncommon	Uncommon
	Gingivitis	Rare	Uncommon
	[...]	[...]	
Blood and lymphatic system disorders	Anaemia	Very common	Very common
	Neutropenia	Very common	Very common
	Leukopenia	Very common	Common
	Thrombocytopenia	Very common	Very common
	Febrile neutropenia	Common	Uncommon
	Lymphopenia	Common	Common
	Pancytopenia	Uncommon	Uncommon
	[...]		
Metabolism and nutrition disorders	Decreased appetite	Very common	Very common
	Hypoalbuminaemia	Common	Uncommon
	Hyperglycaemia	Uncommon	Uncommon
	[...]	[...]	
Nervous system disorders	Dysgeusia	Common	Common
	Dizziness	Uncommon	Common
	Headache	Uncommon	Common
	Neuropathy peripheral	Uncommon	Uncommon
	Paraesthesia	Uncommon	Uncommon
	[...]	[...]	
Vascular disorders	Hypertension	Uncommon	Common
	[...]	[...]	
Respiratory, thoracic and mediastinal disorders	Dyspnoea	Common	Common
		[...]	
	Dysphonia	Uncommon	Uncommon
	[...]	[...]	
	Rhinorrhoea	Rare	Uncommon
	[...]	[...]	

System Organ Class (MedDRA) ^a	Adverse reactions	Frequency	
		Monotherapy	Combination with bevacizumab
Gastrointestinal disorders	Diarrhoea	Very common	Very common
	Vomiting	Very common	Very common
	Nausea	Very common	Very common
	Abdominal pain	Common	Common
	Stomatitis	Common	Very common
	Constipation	Common	Common
	Colitis	[...]	Uncommon
	Mouth ulceration	Uncommon	Common
	Oral disorder	Uncommon	Common
	Abdominal distension	Uncommon	Uncommon
	Anal inflammation	Uncommon	Uncommon
	Dyspepsia	Uncommon	Uncommon
	Flatulence	Uncommon	Uncommon
	[...]	[...]	[...]
Hepatobiliary disorders	Hyperbilirubinaemia	Common	Common
[...]	[...]	[...]	[...]
Skin and subcutaneous tissue disorders	Alopecia	Common	Common
	Dry skin	Common	Common
	Pruritus	Common	Uncommon
	Rash	Common	Uncommon
	Nail disorder	Uncommon	Uncommon
	Palmar-plantar erythrodysesthesia syndrome ^c	Uncommon	Uncommon
	[...]	[...]	[...]
Musculoskeletal and connective tissue disorders	Arthralgia	Uncommon	Common
	Myalgia	Uncommon	Common
	Muscular weakness	Uncommon	Uncommon
	Pain in extremity	Uncommon	Uncommon
	Limb discomfort	[...]	-
[...]	[...]	[...]	
Renal and urinary disorders	Proteinuria	Common	Uncommon
[...]	[...]	[...]	[...]
Reproductive system and breast disorders	Menstrual disorder	Rare	Uncommon

System Organ Class (MedDRA) ^a	Adverse reactions	Frequency	
		Monotherapy	Combination with bevacizumab
General disorders and administration site conditions	Fatigue	Very common	Very common
	Pyrexia	Common	Uncommon
	Mucosal inflammation	Common	Uncommon
	Pain	[...] Uncommon	Uncommon
Investigations	Weight decreased	Common	Common
	Hepatic enzyme increased	Common	Common
	Blood alkaline phosphatase increased	Common	Uncommon
	[...]	[...]	[...]

[...]

Elderly

Patients 65 years of age or older who received Lonsurf as monotherapy had a higher incidence ($\geq 5\%$) of the following treatment-related adverse events compared to patients younger than 65 years: neutropenia (58.9% vs 48.2%), severe neutropenia (41.3% vs 27.9%), anaemia (36.5% vs 25.2%), severe anaemia (14.1% vs 8.9%), decreased appetite (22.6% vs 17.4%), and thrombocytopenia (21.4% vs 12.1%). When Lonsurf is used in combination with bevacizumab, patients 65 years of age or older had a higher incidence ($\geq 5\%$) of the following treatment-related adverse events compared to patients younger than 65 years: neutropenia (75.0% vs 65.1%), severe neutropenia (57.0% vs 41.8%), fatigue (39.0% vs 32.2%), thrombocytopenia (28.0% vs 20.5%), and stomatitis (14.0% vs 8.9%).

[...]

Infections

[...] In the clinical study in combination with bevacizumab, treatment-related infections occurred similarly in patients who received Lonsurf with bevacizumab (2.8%) compared to Lonsurf-treated patients (2.4%).

Proteinuria

[...] In the clinical study in combination with bevacizumab, one patient who received Lonsurf with bevacizumab (0.4%) reported a treatment-related proteinuria which was Grade 2 and none among the Lonsurf-treated patients (see section 4.4).

Radiotherapy

[...] In the clinical study in combination with bevacizumab, no increase of incidence of overall haematological and myelosuppression-related adverse reactions was observed for patients who received prior radiotherapy compared to patients without prior radiotherapy in both arms in SUNLIGHT: Lonsurf with bevacizumab (73.7% versus 77.4%) and in Lonsurf-treated patients (64.7% versus 67.7%).

להלן העדכונים בעלון לצרכן המהווים החמרות (מסומנים **בצהוב**):

2. לפני שימוש בתרופה

[...] פוריות

לונסורף עלולה להשפיע על יכולתך להביא תינוק לעולם. יש לשוחח על כך עם הרופא לפני נטילת התרופה. [...]

4. תופעות לוואי

[...]

תופעות לוואי שכיחות מאוד: עלולות להשפיע על יותר מ- 1 מתוך 10 אנשים:

[...]

• נפיחות ברקמות הריריות בפה

[...]

תופעות לוואי שכיחות: עלולות להשפיע על עד 1 מתוך 10 אנשים:

[...]

• תחושת קוצר נשימה, זיהומים בחזה, בדרכי הנשימה או בריאות

• זיהום ויראלי

• כאב במפרקים

• תחושת סחרחורת, כאב ראש

• לחץ דם גבוה

• כיבים בפה

• כאב שרירים

[...]

העלון לרופא והעלון לצרכן נמצאים בקישור, וכן מפורסמים במאגר התרופות שבאתר משרד הבריאות, וניתן לקבלם מודפסים על ידי פניה לבעל הרישום.

בברכה,

מדיסון פארמה בע"מ